Major developments in the treatment of multiple myeloma (MM) over the past decade have
led to a continued improvement in survival. Significant progress has been made with deeper …

The prognosis for patients multiple myeloma (MM) has improved substantially over the past
decade with the development of new, more effective chemotherapeutic agents and regimens …

Disease overview: Multiple myeloma accounts for approximately 10% of hematologic
malignancies. Diagnosis: The diagnosis requires 10% or more clonal plasma cells on bone …

Disease overview Multiple myeloma accounts for approximately 10% of hematologic
malignancies. Diagnosis The diagnosis requires 10% or more clonal plasma cells on bone …

A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become
available, extending progression-free and overall survival for patients in meaningful ways …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Multiple myeloma is almost invariably fatal despite a wide variety of chemotherapeutic and
supportive treatment options. There are several unresolved problems with existing …

Autologous stem cell transplant (SCT) improves survival in multiple myeloma (MM) and
remains the standard of care for eligible patients. Nearly a third of patients with newly …